Arrowhead Pharmaceuticals (ARWR) Non-Current Debt (2011 - 2026)
Arrowhead Pharmaceuticals (ARWR) posted Non-Current Debt of $159.6 million for Q1 2026, down 2.13% on a QoQ basis from $163.1 million in Q4 2025, and down 23.59% year-over-year from $208.9 million in Q1 2025.
Arrowhead Pharmaceuticals (ARWR) Non-Current Debt (2011 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals' Non-Current Debt history runs 10 years deep, the most recent figure standing at $159.6 million for Q1 2026.
- Quarterly Non-Current Debt fell 23.59% year-over-year to $159.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $159.6 million (down 23.59% YoY) and the FY2025 annual result came in at $214.9 million, down 45.35% from the prior year.
- Non-Current Debt was $159.6 million for Q1 2026 at Arrowhead Pharmaceuticals, down from $163.1 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $407.8 million in Q4 2024 and bottomed at $159.6 million in Q1 2026.
- A 3-year average of $249.7 million and a median of $208.9 million in 2025 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2025 — Non-Current Debt plunged 60.0% — and 2026, when it slipped 23.59%.
- Arrowhead Pharmaceuticals' Non-Current Debt stood at $407.8 million in 2024, then plunged by 60.0% to $163.1 million in 2025, then fell by 2.13% to $159.6 million in 2026.
- Business Quant data shows ARWR's Non-Current Debt at $159.6 million in Q1 2026, $163.1 million in Q4 2025, and $214.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 105.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 842.92 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Arrowhead Pharmaceuticals | 11.98 Bn | 10.18 Bn | - | 159.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 159.64 Mn |
| Dec 31, 2025 | 163.11 Mn |
| Sep 30, 2025 | 214.88 Mn |
| Jun 30, 2025 | 200.33 Mn |
| Mar 31, 2025 | 208.93 Mn |
| Dec 31, 2024 | 407.79 Mn |
| Sep 30, 2024 | 393.18 Mn |
| Sep 30, 2019 | 2.70 Mn |
| Jun 30, 2019 | 2.70 Mn |
| Mar 31, 2019 | 2.70 Mn |
| Dec 31, 2018 | 2.30 Mn |
| Sep 30, 2018 | 2.10 Mn |
| Jun 30, 2018 | 2.16 Mn |
| Mar 31, 2018 | 2.22 Mn |
| Dec 31, 2017 | 2.27 Mn |
| Sep 30, 2017 | 2.33 Mn |
| Jun 30, 2017 | 2.38 Mn |
| Mar 31, 2017 | 2.43 Mn |
| Dec 31, 2016 | 2.48 Mn |
| Sep 30, 2016 | 2.53 Mn |